EpicentRx’s Oncolytic Virus-delivered TGFβ Inhibitor, AdAPT-001, Receives FDA Fast Track Designation for Recurrent or Refractory Soft Tissue Sarcoma Treatment
Dec 5, 2024
AdAPT-001 received Fast Track Designation. So, what, you say? So, let’s dance. Click on the image to play.
